Lilly and Company has announced a definitive agreement to acquire Centessa Pharmaceuticals' orexin receptor 2 (OX2R) agonist program in a deal potentially worth $600 million. The transaction includes a significant upfront payment of $325 million, with an additional $275 million tied to future milestones. This strategic acquisition is set to bolster Lilly's efforts in developing innovative treatments for sleep apnea and other complex neurological disorders.
Strategic Expansion in Neuroscience
Lilly's acquisition strategically strengthens its neuroscience portfolio by targeting the fundamental mechanisms that govern the sleep-wake cycle. The OX2R agonist program is specifically designed to activate a key receptor in the brain responsible for promoting and maintaining wakefulness. This novel therapeutic approach holds considerable promise for developing effective new options for patients suffering from conditions like obstructive sleep apnea.
A Clinically Validated Asset
The centerpiece of the acquisition is a clinical-stage molecule, formerly designated CB-010, which has already demonstrated encouraging results in early human trials. In a completed Phase 1 study, the compound successfully established proof-of-mechanism by producing a statistically significant increase in wakefulness compared to a placebo. These positive early findings provide a strong scientific foundation for Lilly to advance the program into later-stage clinical development.
Financial Details and Company Outlook
The financial terms of the agreement provide Centessa with a substantial upfront cash payment of $325 million, securing immediate value for its shareholders. An additional $275 million in contingent payments is available to Centessa upon the successful achievement of specific development and regulatory milestones. This tiered payment structure reflects the program's current stage while acknowledging its significant future commercial potential.
This transaction provides Centessa with a significant infusion of non-dilutive capital, which will be instrumental in advancing its remaining pipeline of innovative assets. Saurabh Saha, CEO of Centessa, expressed that the deal validates the potential of their orexin program and its scientific underpinnings. The company can now sharpen its focus on developing other first-in-class or best-in-class therapies for patients with serious diseases.
For Eli Lilly, this acquisition represents a calculated and strategic move to expand its leadership position in the treatment of challenging neurological disorders. Mark Mintun, group vice president of neuroscience research and development at Lilly, described the program as a natural extension of the company's existing research efforts. Lilly is committed to leveraging this promising asset to create a differentiated and impactful treatment for patients with sleep apnea.
The acquisition of Centessa's OX2R agonist program by Eli Lilly marks a significant development in the pursuit of new treatments for sleep-related disorders. This mutually beneficial deal provides Centessa with substantial funding while positioning Lilly at the forefront of developing a novel therapy for sleep apnea. The transaction, subject to customary closing conditions and regulatory approvals, is anticipated to be finalized in the third quarter of 2024.